SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

Clinical trial NCT07187531 · RECRUITING

Trial details

NCT number: NCT07187531
Sponsor: SAb Biotherapeutics, Inc.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Type 1 Diabetes

Start date: 2025-11-25
Primary completion: 2027-11-01
Enrollment: 159

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.